Compare · FMS vs PGNY
FMS vs PGNY
Side-by-side comparison of Fresenius Medical Care AG (FMS) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FMS and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS is the larger of the two at $12.36B, about 5.9x PGNY ($2.11B).
- Over the past year, FMS is down 18.0% and PGNY is up 25.9% - PGNY leads by 43.9 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- PGNY has more recent analyst coverage (25 ratings vs 24 for FMS).
- Company
- Fresenius Medical Care AG
- Progyny Inc.
- Price
- $22.16+0.18%
- $26.88-2.06%
- Market cap
- $12.36B
- $2.11B
- 1M return
- +0.43%
- -0.43%
- 1Y return
- -18.00%
- +25.94%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 5
- 5
- Recent ratings
- 24
- 25
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest FMS
- SEC Form 6-K filed by Fresenius Medical Care AG
- Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth
- Fresenius Medical downgraded by Berenberg
- Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care Announces Publication of a Multinational Real-World Evidence Study Associating High-Volume Hemodiafiltration with Lower Mortality Risk Than Conventional Hemodialysis
- SEC Form 6-K filed by Fresenius Medical Care AG
- Amendment: SEC Form SCHEDULE 13D/A filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
Latest PGNY
- SEC Form 4 filed by Progyny Inc.
- Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting
- Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics
- EVP, GC Swartz Allison sold $101,868 worth of shares (3,903 units at $26.10) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 75,816 units (SEC Form 4)
- Chief Product Officer Clapp Geoffrey covered exercise/tax liability with 819 shares, decreasing direct ownership by 1% to 59,009 units (SEC Form 4) to cover taxes
- Amendment: Director Gordon Kevin K exercised 22,000 shares at a strike of $13.00, covered exercise/tax liability with 10,500 shares and sold $311,858 worth of shares (11,500 units at $27.12) (SEC Form 4)
- Director Gordon Kevin K exercised 22,000 shares at a strike of $13.00, covered exercise/tax liability with 10,500 shares and sold $321,358 worth of shares (11,500 units at $27.94) (SEC Form 4)
- SEC Form 144 filed by Progyny Inc.
- CHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 5,361 shares, decreasing direct ownership by 0.66% to 806,111 units (SEC Form 4) to satisfy tax liability
- EVP, GC Swartz Allison covered exercise/tax liability with 1,307 shares, decreasing direct ownership by 2% to 79,719 units (SEC Form 4) (withholding tax)